Literature DB >> 25512528

Allosteric activation of ADAMTS13 by von Willebrand factor.

Joshua Muia1, Jian Zhu1, Garima Gupta1, Sandra L Haberichter2, Kenneth D Friedman2, Hendrik B Feys3, Louis Deforche4, Karen Vanhoorelbeke4, Lisa A Westfield1, Robyn Roth5, Niraj Harish Tolia6, John E Heuser5, J Evan Sadler7.   

Abstract

The metalloprotease ADAMTS13 cleaves von Willebrand factor (VWF) within endovascular platelet aggregates, and ADAMTS13 deficiency causes fatal microvascular thrombosis. The proximal metalloprotease (M), disintegrin-like (D), thrombospondin-1 (T), Cys-rich (C), and spacer (S) domains of ADAMTS13 recognize a cryptic site in VWF that is exposed by tensile force. Another seven T and two complement C1r/C1s, sea urchin epidermal growth factor, and bone morphogenetic protein (CUB) domains of uncertain function are C-terminal to the MDTCS domains. We find that the distal T8-CUB2 domains markedly inhibit substrate cleavage, and binding of VWF or monoclonal antibodies to distal ADAMTS13 domains relieves this autoinhibition. Small angle X-ray scattering data indicate that distal T-CUB domains interact with proximal MDTCS domains. Thus, ADAMTS13 is regulated by substrate-induced allosteric activation, which may optimize VWF cleavage under fluid shear stress in vivo. Distal domains of other ADAMTS proteases may have similar allosteric properties.

Entities:  

Keywords:  allosteric regulation; hemostasis; metalloproteases

Mesh:

Substances:

Year:  2014        PMID: 25512528      PMCID: PMC4284596          DOI: 10.1073/pnas.1413282112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

Review 1.  The ADAMTS(L) family and human genetic disorders.

Authors:  Carine Le Goff; Valérie Cormier-Daire
Journal:  Hum Mol Genet       Date:  2011-08-31       Impact factor: 6.150

2.  High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women.

Authors:  Helena M Andersson; Bob Siegerink; Brenda M Luken; James T B Crawley; Ale Algra; David A Lane; Frits R Rosendaal
Journal:  Blood       Date:  2011-11-22       Impact factor: 22.113

3.  ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice.

Authors:  Chintan Gandhi; Mohammad Moshahid Khan; Steven R Lentz; Anil K Chauhan
Journal:  Blood       Date:  2011-11-28       Impact factor: 22.113

4.  A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?

Authors:  K Soejima; N Mimura; M Hirashima; H Maeda; T Hamamoto; T Nakagaki; C Nozaki
Journal:  J Biochem       Date:  2001-10       Impact factor: 3.387

Review 5.  Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices.

Authors:  Jorge Suarez; Chetan B Patel; G Michael Felker; Richard Becker; Adrian F Hernandez; Joseph G Rogers
Journal:  Circ Heart Fail       Date:  2011-11       Impact factor: 8.790

6.  Partial amino acid sequence of purified von Willebrand factor-cleaving protease.

Authors:  H E Gerritsen; R Robles; B Lämmle; M Furlan
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.

Authors:  K Fujikawa; H Suzuki; B McMullen; D Chung
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

8.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

9.  An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura.

Authors:  J Muia; W Gao; S L Haberichter; L Dolatshahi; J Zhu; L A Westfield; S C Covill; K D Friedman; J E Sadler
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

10.  Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.

Authors:  Antoine Rauch; Paulette Legendre; Olivier D Christophe; Jenny Goudemand; Eric van Belle; André Vincentelli; Cécile V Denis; Sophie Susen; Peter J Lenting
Journal:  Thromb Haemost       Date:  2014-07-17       Impact factor: 5.249

View more
  40 in total

1.  Structural Architecture of Prothrombin in Solution Revealed by Single Molecule Spectroscopy.

Authors:  Nicola Pozzi; Dominika Bystranowska; Xiaobing Zuo; Enrico Di Cera
Journal:  J Biol Chem       Date:  2016-07-19       Impact factor: 5.157

2.  Hairpin and allosteric regulation in ADAMTS13.

Authors:  Dominic W Chung
Journal:  Blood       Date:  2019-04-25       Impact factor: 22.113

3.  ADAMTS13 and von Willebrand factor interactions.

Authors:  Catherine B Zander; Wenjing Cao; X Long Zheng
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

4.  ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro.

Authors:  Eric M Ostertag; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; X Long Zheng; Douglas B Cines; Don L Siegel
Journal:  Transfusion       Date:  2016-04-04       Impact factor: 3.157

5.  Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13.

Authors:  L Deforche; E Roose; A Vandenbulcke; N Vandeputte; H B Feys; T A Springer; L Z Mi; J Muia; J E Sadler; K Soejima; H Rottensteiner; H Deckmyn; S F De Meyer; K Vanhoorelbeke
Journal:  J Thromb Haemost       Date:  2015-10-20       Impact factor: 5.824

6.  Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels.

Authors:  Qianyi Ma; Paula M Jacobi; Brian T Emmer; Colin A Kretz; Ayse Bilge Ozel; Beth McGee; Chava Kimchi-Sarfaty; David Ginsburg; Jun Z Li; Karl C Desch
Journal:  Blood Adv       Date:  2017-06-19

7.  Exploring the "minimal" structure of a functional ADAMTS13 by mutagenesis and small-angle X-ray scattering.

Authors:  Jian Zhu; Joshua Muia; Garima Gupta; Lisa A Westfield; Karen Vanhoorelbeke; Niraj H Tolia; J Evan Sadler
Journal:  Blood       Date:  2019-01-28       Impact factor: 22.113

8.  Phylogenetic and functional analysis of ADAMTS13 identifies highly conserved domains essential for allosteric regulation.

Authors:  Joshua Muia; Jian Zhu; Suellen C Greco; Karen Vanhoorelbeke; Garima Gupta; Lisa A Westfield; J Evan Sadler
Journal:  Blood       Date:  2019-01-30       Impact factor: 22.113

9.  N-linked glycan stabilization of the VWF A2 domain.

Authors:  Christopher J Lynch; David A Lane
Journal:  Blood       Date:  2016-01-14       Impact factor: 22.113

10.  Identification of extant vertebrate Myxine glutinosa VWF: evolutionary conservation of primary hemostasis.

Authors:  Marianne A Grant; David L Beeler; Katherine C Spokes; Junmei Chen; Harita Dharaneeswaran; Tracey E Sciuto; Ann M Dvorak; Gianluca Interlandi; José A Lopez; William C Aird
Journal:  Blood       Date:  2017-09-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.